As Sweden's Riksbank reduces borrowing costs and the European economy shows signs of recovery, investors are increasingly looking for growth opportunities in the Swedish market. High insider ownership often signals confidence from those closest to the company, making it a key factor to consider when evaluating potential growth stocks.
Top 10 Growth Companies With High Insider Ownership In Sweden
| Name | Insider Ownership | Earnings Growth |
| CTT Systems (OM:CTT) | 16.9% | 24.8% |
| Truecaller (OM:TRUE B) | 29.5% | 21.6% |
| Fortnox (OM:FNOX) | 21.1% | 22.6% |
| Biovica International (OM:BIOVIC B) | 18.8% | 73.8% |
| Magle Chemoswed Holding (OM:MAGLE) | 14.9% | 72.2% |
| BioArctic (OM:BIOA B) | 34% | 101% |
| KebNi (OM:KEBNI B) | 37.8% | 86.1% |
| Yubico (OM:YUBICO) | 37.5% | 42.5% |
| InCoax Networks (OM:INCOAX) | 19% | 115.5% |
| Calliditas Therapeutics (OM:CALTX) | 12.7% | 51.9% |
Here we highlight a subset of our preferred stocks from the screener.
BioArctic (OM:BIOA B)
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) develops biological drugs for central nervous system disorders in Sweden and has a market cap of SEK15.35 billion.
Operations: Revenue from biotechnology amounts to SEK252.21 million.
Insider Ownership: 34%
Earnings Growth Forecast: 101% p.a.
BioArctic exhibits strong growth potential with high insider ownership, evidenced by a forecasted revenue growth of 39.5% annually and expected profitability within three years. Despite recent volatility, the stock trades significantly below its estimated fair value. Recent earnings show improved sales at SEK 49.84 million for Q2 2024, up from SEK 2.71 million a year ago, though net losses remain substantial. Key product advancements include exidavnemab's positive phase-1 results and Leqembi's approval in multiple countries for Alzheimer's treatment.
- Click here and access our complete growth analysis report to understand the dynamics of BioArctic.
- According our valuation report, there's an indication that BioArctic's share price might be on the cheaper side.
Fortnox (OM:FNOX)
Simply Wall St Growth Rating: ★★★★★★
Overview: Fortnox AB (publ) offers financial and administrative software solutions for small and medium-sized businesses, accounting firms, and organizations, with a market cap of SEK36.64 billion.
Operations: Revenue segments for Fortnox AB (publ) include Businesses (SEK378 million), Marketplaces (SEK160 million), Core Products (SEK734 million), Accounting Firms (SEK352 million), and Financial Services (SEK249 million).
Insider Ownership: 21.1%
Earnings Growth Forecast: 22.6% p.a.
Fortnox is a growth company with substantial insider ownership and strong earnings prospects. Insiders have been actively buying shares, reflecting confidence in the company's future. Recent earnings reports show significant revenue growth, with Q2 2024 sales at SEK 515 million compared to SEK 404 million a year ago. Earnings are forecast to grow at an annual rate of 22.6%, outpacing the Swedish market's average, while the stock trades below its estimated fair value by 23.4%.
- Click to explore a detailed breakdown of our findings in Fortnox's earnings growth report.
- The analysis detailed in our Fortnox valuation report hints at an deflated share price compared to its estimated value.
HMS Networks (OM:HMS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: HMS Networks AB (publ) provides products that enable industrial equipment to communicate and share information globally, with a market cap of SEK22.16 billion.
Operations: HMS Networks generates revenue primarily from its Wireless Communications Equipment segment, which accounted for SEK3.01 billion.
Insider Ownership: 12.6%
Earnings Growth Forecast: 29.6% p.a.
HMS Networks shows strong growth potential with earnings expected to grow 29.6% annually, outpacing the Swedish market's 16%. Revenue is forecast to rise by 16% per year, though profit margins have declined from 20.1% to 14%. Insiders have been buying more shares than selling in the past three months, indicating confidence. Recent earnings reports show Q2 sales at SEK 845 million compared to SEK 703 million last year, despite a drop in net income from SEK 116 million to SEK 34 million.
- Unlock comprehensive insights into our analysis of HMS Networks stock in this growth report.
- The analysis detailed in our HMS Networks valuation report hints at an inflated share price compared to its estimated value.
Make It Happen
- Discover the full array of 91 Fast Growing Swedish Companies With High Insider Ownership right here.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if BioArctic might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About OM:BIOA B
BioArctic
Develops biological drugs for patients with disorders of the central nervous system in Sweden.
Exceptional growth potential with flawless balance sheet.
